Source: SEBI
What would have to hold for each case — not a price target or a projected figure. CapitSignal does not forecast where this stock trades.
The company successfully expands its market share in the cardiovascular device segment.
Integris Medtech is the second largest Indian coronary stent manufacturer with a 22.0% market share in drug-eluting stents for Fiscal 2025.
The healthcare sector in India continues to grow at a projected CAGR of 26.0% from 2023 to 2025.
The Indian healthcare sector is projected to grow from US $372.0 billion in 2023 to US $638.0 billion by 2025.
The company maintains its current revenue trajectory as outlined in the prospectus.
Integris Medtech reported revenue from operations of ₹19,024.66 million for Fiscal 2025, showing consistent growth from previous years.
The company continues to rely on strategic acquisitions for growth.
The business model relies significantly on acquisitions, which may expose the company to integration and execution risks.
Regulatory approvals are delayed or denied, impacting product marketing.
Delays in obtaining, renewing, or maintaining key regulatory approvals may restrict the company's ability to market and sell products.
The company faces significant operational disruptions due to product recalls.
Self-corrective quality issues related to product holds and recalls may result in operational disruption, financial loss, and reputational harm.